BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about BEIGENE, LTD.
05/17BeiGene to Open Regional Office in Switzerland
MT
05/17BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Swi..
BU
05/17BeiGene, Ltd. Announces the Opening of a New Regional Office in Basel, Switzerland
CI
05/12BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hemato..
BU
05/11Asian ADRs Move Higher in Wednesday Trading
MT
05/10Asian ADRs Climb Higher in Tuesday Trading
MT
05/09Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra..
MT
05/09INSIDER SELL : BeiGene
MT
05/05BeiGene Swings to Q1 Net Loss as Revenue Declines
MT
05/05Earnings Flash (BGNE) BEIGENE Reports Q1 Revenue $306.6M, vs. Street Est of $300.4M
MT
05/05BeiGene Reports First Quarter 2022 Financial Results
BU
05/05BeiGene, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/04BeiGene Says China Gives Conditional Approval to Blincyto Injection for Pediatric Acute..
MT
05/04BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for P..
BU
05/04Beigene Announces the Approval in China of BLINCYTO® for Injection for Pediatric Patien..
CI
04/29BeiGene Breaks Ground on Flagship US Facility in New Jersey; Shares Climb
MT
04/29BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton Wes..
BU
04/29Beigene Breaks Ground on New Manufacturing and Clinical R&D Center At the Princeton Wes..
CI
04/28BEIGENE : Financial Information - Form 8-K
PU
04/28BeiGene's Brukinsa Secures Uruguay's Approval For Lymphoma, Waldenstrom's Macroglobulin..
MT
04/28BeiGene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, ..
BU
04/28Beigene Announces BRUKINSA (zanubrutinib) Approval in Uruguay in Mantle Cell Lymphoma, ..
CI
04/27BeiGene, Ltd. Announces Global Phase 3 Trial of PD-1 Inhibitor, Tislelizumab, in Combin..
CI
04/27BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual..
BU
04/27BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual..
CI
04/27Global Phase 3 Trial of BeiGene's PD-1 Inhibitor, Tislelizumab, in Combination with Che..
BU
04/27BeiGene Phase 3 Trial for Tislelizumab Meets Primary Endpoint
DJ
04/26BeiGene Introduces Global Environmental, Social, and Governance Strategy
BU
04/25Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene
AQ
04/25Biocytogen Signs Renmab /Renlite Licensing Agreement with Beigene
CI
04/21US Adds Luckin Coffee, Li Auto, Others to SEC's List of HFCAA Noncompliant Firms
MT
04/21BeiGene Provides Grant to Crossroads4Hope to Fund Psychosocial Support Programs for Can..
BU
04/20BEIGENE : China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamo..
PU
04/19BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tis..
BU
04/19BeiGene Presents Updated Results from Phase 3 RATIONALE-309 Trial of PD-1 Inhibitor Tis..
CI
04/18Beigene's Cancer Drug Gets Regulator Approval in China
MT
04/15China NMPA Approves Tislelizumab for Patients with Second-Line Esophageal Squamous Cell..
BU
04/15BeiGene, Ltd. Announces China National Medical Products Administration Approves Tisleli..
CI
04/15BeiGene Gets China Approval for Tislelizumab Cancer Treatment
DJ
04/12BEIGENE : Announces European Medicines Agency Acceptance of Marketing Authorization Applic..
PU
04/12Morgan Stanley Adjusts BeiGene's Price Target to $338 from $330, Keeps Overweight Ratin..
MT
04/11Asian ADRs Move Lower in Monday Trading
MT
04/11Beigene Announces IRC Determines Brukinsa® (Zanubrutinib) Demonstrates Superior Overall..
CI
04/11BeiGene's Brukinsa Improves Overall Response Rate in Chronic Lymphocytic Leukemia in Ph..
MT
04/11IRC Determines BRUKINSA® (Zanubrutinib) Demonstrates Superior Overall Response Rate Ver..
BU
04/08BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors ..
BU
04/08BeiGene to Present Clinical Results and Biomarker Data on Tislelizumab in Solid Tumors ..
CI
04/06BeiGene Says European Regulator Accepts Marketing Authorization Applications for Tislel..
MT
04/06BeiGene Announces European Medicines Agency Acceptance of Marketing Authorization Appli..
BU
04/06Beigene, Ltd. Announces European Medicines Agency Acceptance of Marketing Authorization..
CI
04/04China’s Securities Watchdog Eases Rules on Financial Inspections of Offshore List..
MT
04/03SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beige..
PR
04/01Baidu Explores Options Amid US Delisting Risk; Hong Kong Shares Fall 6%
MT
03/31Hong Kong Stocks Retreat from Four-Week High; Two Out of Three Newcomers Gain in Tradin..
MT
03/25SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beige..
PR
03/25BEIGENE : Current Report (Form 8-K)
PU
03/25Hong Kong Stocks Finish Lower; Weibo Slides 5%
MT
03/25Weibo to Explore All Options Amid US Delisting Risk
MT
03/24Asian ADRs Move Lower in Thursday Trading
MT
03/22Beijing Asks Alibaba, JD.com, Others to Brace For More US Audit Disclosures
MT
03/22Exclusive - Chinese regulators ask some U.S.-listed firms to prepare for audit disclosu..
RE
03/22Chinese regulators ask some U.S.-listed firms to prepare for audit disclosures - source..
RE
03/17BEIGENE : China NMPA Approves Tislelizumab for Patients with Microsatellite Instability-Hi..
PU
03/17SVB Leerink Cuts BeiGene to Market Perform From Outperform, Price Target to $177 From $..
MT
03/16SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beige..
PR
03/16ADRs End Higher; Bilibili Gains 48%
DJ
03/16BeiGene Up Over 22%, on Pace for Largest Percent Increase Since November 2019 -- Data T..
DJ
03/15SECTOR UPDATE : Health Care Stocks Gaining Steam in Late Trade
MT
03/15SECTOR UPDATE : Health Care Stocks Advancing Tuesday
MT
03/15BeiGene, Medison Pharma Say Israel Approves Brukinsa to Treat Waldenstrom's Macroglobul..
MT
03/15BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA..
BU
03/15BeiGene and Medison Announce Approval and National Reimbursement in Israel for BRUKINSA..
CI
03/14Chinese Regulators Grant Conditional OK to BeiGene's Solid Tumor Treatment
MT
03/13Yum China, Four Others Face Delisting Risk in US Over Auditing Violations
MT
03/11Yum China, BeiGene Among Five Firms Facing Delisting Over Audit Review Act -- Shares Ex..
MT
1  2  3  4  5  6  7  8  9  10Next